mash semaglutide targets molecular pathways beyond weight loss Wegovy approved for MASH with
Description
Same active ingredient as Ozempic but licenced specifically for weight management at a higher dose
Risk Factors Age over 50 Family history of colorectal cancer or polyps Inflammatory bowel disease (ulcerative colitis, Crohns) Diet high in red/processed meat Low fiber intake Obesity Smoking Alcohol use Genetic syndromes: Familial adenomatous polyposis (FAP) Lynch syndrome (HNPCC) Common Symptoms Early stages may be silent
Results Thirteen RCTs with 13,761 participants were analyzed
This means you feel fuller longer and eat less, and it helps your body use blood sugar more effectively
